Health Care

Alcidion Group’s AI‑driven Miya Precision platform powers interoperable health‑IT across ANZ, UK, NZ, and beyond—backed by debt‑free, high‑margin contracts and a global investor roadshow.

Discover how Cigna Group’s 2025 results show resilience, with palm oil price gains and a cashew turnaround, driving future growth and shareholder value.

Merck’s 29 June 2026 share rise shows a resilient healthcare stock: strong valuation, growth‑oriented R&D, value‑based care strategy, and cost‑efficient operations that boost investor confidence.

ASIC completes investigations into Humm Group’s Cards AU and commercial subsidiaries, finding governance gaps but no enforcement yet. Learn how the fintech is tightening controls and what it means for investors.

How Astellas’ Enzalutamide expansion reshapes oncology pricing, reimbursement models, and market share—unlocking $150 million in revenue and setting a new benchmark for value‑based drug delivery.

Fisher & Paykel Healthcare’s Q4 2025 update shows robust cash, 12% cash‑flow growth, and a 55% margin—fueling R&D, value‑based pricing, and strategic expansion in global healthcare markets.

Explore how Eli Lilly’s AI‑driven R&D and targeted acquisitions are reshaping its pipeline, cutting costs, and battling patent cliffs in a competitive pharma market.

Perennial ETF spots ResMed as a top health‑tech pick, noting its strong EBITDA growth, ESG focus, and growing reimbursement pathways that boost ROI for patients and investors.

Pro Medic Us Ltd’s minor ETF holdings reveal a med‑tech firm poised for telehealth growth, yet lagging ESG and margin metrics—watch its strategy for upside in a tightening market.

AbbVie’s $109 billion Apogee Therapeutics deal boosts gene‑therapy pipelines, offsets patent cliffs, and strengthens its market moat, positioning it for sustained growth in 2026.